title: Lorcaserin Use in the Management of Morbid Obesity in a Pre-Liver Transplant Patient.
abstract: Management of obesity and decompensated cirrhosis in those requiring liver transplantation (LT) is a challenging dilemma. Because of concerns for perioperative complications, many centers avoid transplant in those with a body mass index (BMI) greater than 40 kg/m(2) . Bariatric surgery is associated with increased risk attributable to complications of portal hypertension, including variceal rupture. Therefore, weight loss and LT options are limited. Several new classes of weight loss drugs are commercially available, including the anoretic, lorcaserin. This case illustrates the successful use of lorcaserin in a morbidly obese individual with decompensated cirrhosis evaluated for LT listing. (Hepatology 2016;64:301-302).
authors.affiliation: Department of Hepatology, Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX.
authors.forename: Julio A
authors.initials: JA
authors.lastname: Gutierrez
authors.affiliation: Department of Hepatology, Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX.
authors.forename: Carmen
authors.initials: C
authors.lastname: Landaverde
authors.affiliation: Department of Hepatology, Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX.
authors.forename: Jennifer T
authors.initials: JT
authors.lastname: Wells
authors.affiliation: Department of Hepatology, Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX.
authors.forename: Fred
authors.initials: F
authors.lastname: Poordad
mesh_terms: D001552:Benzazepines / Q000627:therapeutic use*; D006801:Humans; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D009767:Obesity, Morbid / Q000188:drug therapy*
chemical_list: D001552:Benzazepines; C506658:lorcaserin